Report overview
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
This report aims to provide a comprehensive presentation of the global market for Recombinant Plasma Proteins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Plasma Proteins. This report contains market size and forecasts of Recombinant Plasma Proteins in global, including the following market information:
Global Recombinant Plasma Proteins Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Recombinant Plasma Proteins market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Chinese Hamster Ovary (CHO) Cell Line Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Recombinant Plasma Proteins include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group and Pfizer, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Plasma Proteins companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Plasma Proteins Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Recombinant Plasma Proteins Market Segment Percentages, by Type, 2022 (%)
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Global Recombinant Plasma Proteins Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Recombinant Plasma Proteins Market Segment Percentages, by Application, 2022 (%)
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
Global Recombinant Plasma Proteins Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Recombinant Plasma Proteins Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Plasma Proteins revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Recombinant Plasma Proteins revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Plasma Proteins, market overview.
Chapter 2: Global Recombinant Plasma Proteins market size in revenue.
Chapter 3: Detailed analysis of Recombinant Plasma Proteins company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Plasma Proteins in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
